EU "soft-justice" for Boehringer Ingelheim but are patent thickets legal?
This article was originally published in Scrip
The European Commission has dropped its investigation into allegations made by the Spanish firm, Almirall, that Boehringer Ingelheim had misused the patent system to exclude potential competition in the chronic obstructive pulmonary disease space. The two companies have reached an agreement, the commission announced yesterday.
You may also be interested in...
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.